Medtronic is upping the ante in patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic's InterStim device, an implanted ...
Stimguard LLC will begin enrollment for a head-to-head study of its Chronic Affarent Nerve Stimulator (CAN-stim) against Medtronic plc's gold standard Interstim device in treatment of urgency urinary ...
Medtronic continues to up its game in sacral neuromodulation. FDA approved InterStim X, the next generation of the company's InterStim portfolio's recharge-free device. Medtronic said implants have ...
Sept 19 (Reuters) - Medical device maker Axonics has convinced a jury in California federal court that it did not violate rival Medtronic's (MDT.N), opens new tab patent rights in nerve-stimulation ...
BROOKLYN CENTER, Minn. — Medtronic is giving a group of international VIPs a rare, behind the scenes tour of its operations this week. In this case, VIP stands for Very Important Patients. "This is ...
Axonics gets a new chance to invalidate two Medtronic nerve-stimulation patents Related Medtronic lawsuit scheduled for trial in August The U.S. Court of Appeals for the Federal Circuit said, opens ...
The race to treat a number of health conditions using neurostimulation technology is a marathon, not a sprint—but Medtronic and Axonics Modulation Technologies are still aiming for a photo finish. For ...
Dublin-based Medtronic plc has filed a PMA supplement with the U.S. FDA for its next-generation, implantable sacral neuromodulation (SNM) device, Interstim Micro, and for its Interstim Surescan MRI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results